CSP Inc. — Q2 FY2023 Form 10-Q
Reporting period: Quarter and six months ended March 31, 2023. CSP operates Technology Solutions (TS) and High Performance Products (HPP), serving commercial and defense customers. Financial amounts below are in millions unless otherwise noted.
Financial performance
| Metric | Q2 FY2023 | Q2 FY2022 | Six months FY2023 | Six months FY2022 |
|---|---|---|---|---|
| Revenue | $13.27 | $11.98 | $31.61 | $24.35 |
| Gross profit / margin | $4.99 / 37.6% | $4.20 / 35.0% | $10.81 / 34.2% | $7.81 / 32.1% |
| Operating income (loss) | $0.24 | ($0.02) | $1.60 | ($0.42) |
| Net income (loss) | $0.32 | $0.16 | $1.28 | ($0.21) |
| Diluted EPS | $0.07 | $0.03 | $0.27 | ($0.05) |
| Operating cash flow | Not reported quarterly | Not reported quarterly | ($4.53) | $1.27 |
Second-quarter revenue rose 11% year over year; six-month revenue increased 30%. For the quarter, TS revenue grew 9% to $11.79 million and HPP grew 29% to $1.48 million. Six-month revenue gains came from both segments: TS rose 25% to $27.65 million and HPP rose 80% to $3.97 million. HPP’s higher-margin product mix lifted its gross margin, while TS gross margin was broadly stable.
For the six months, the company’s operating cash outflow primarily reflected an $8.48 million decrease in accounts payable and accrued expenses, a $2.04 million inventory build, and other working-capital movements. Cash and cash equivalents fell $10.67 million from September 30, 2022.
Balance sheet and liquidity
- At March 31, 2023, cash was $13.31 million and held-to-maturity Treasury bills were $3.53 million; total current assets were $50.90 million and current liabilities were $19.52 million.
- Working capital was approximately $31.38 million. Total assets were $66.02 million, total liabilities $24.58 million, and shareholders’ equity $41.45 million.
- Borrowings were $1.34 million on the inventory line of credit and $0.44 million of current notes payable; no noncurrent notes payable remained. The $15 million inventory credit facility had $13.7 million available, and the company reported compliance with its covenants.
- Management stated that cash, expected operating cash generation, and available credit should meet working-capital and capital-expenditure needs for at least 12 months from the filing date.
Changes, outlook, and risks
- Six-month operating results improved from a $0.42 million operating loss to $1.60 million operating income, supported by higher sales and gross profit. Net income was partly offset by a $0.62 million foreign-exchange loss, compared with a gain in the prior-year period.
- HPP’s six-month product revenue included fulfillment of a roughly $1.8 million Myricom order placed in FY2022 but delayed by supply-chain constraints; it was recognized in FY2023. This affects period comparability.
- The filing provides no numerical revenue or earnings guidance. Management cited continuing supply-chain delays, component shortages and inflationary price pressures, and noted its inability to estimate the pandemic’s future business impact. The Russia-Ukraine conflict had no direct significant revenue impact to date, but could affect suppliers, trade, cyber risk, demand, and foreign exchange.
- Risks include reliance on a small number of customers, U.S. federal-government contracts, and sole-source component suppliers. One customer represented 49% of accounts receivable and long-term receivables at quarter-end. One vendor represented approximately 43% of specified accounts payable and other noncurrent liabilities, down from 63% at September 30, 2022.
- Tax expense rose to $0.20 million for the six months; management cited state minimum taxes and required capitalization of R&D costs under IRC Section 174, partly offset by tax attributes. The company maintained a full valuation allowance.
- The board declared and paid two quarterly dividends of $0.03 per share during the six-month period. Management reported effective disclosure controls and no material change in internal control; the filing reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether the sharp decline in operating cash flow is temporary, particularly the timing of vendor payments and inventory purchases.
- Collection timing and credit exposure for long-term customer receivables, including the concentrated customer balance; the filing reports no past-due amounts in these receivables.
- Whether HPP’s elevated margins and sales growth are repeatable given product mix and the delayed Myricom order.
- Current supply availability and dependence on sole-source suppliers, as well as the effect of foreign-exchange movements.
- Liquidity and covenant headroom, and the impact of R&D tax capitalization and the valuation allowance on future tax expense.